[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"occipital-neuralgia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:occipital-neuralgia":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":4},"100643683","prospective-case-series-evaluating-6-month-and-12-month-outcomes-after-cryoneurolysis-for-chronic-pain-100643683",false,"NCT07639060","Prospective Case Series Evaluating 6-Month and 12-Month Outcomes After Cryoneurolysis for Chronic Pain","Inclusion Criteria:\n\n* Diagnosis of chronic pain (generally pain duration of at least 3-6 months) localized to an anatomical region appropriate for cryoneurolysis as determined by the treating physician.\n* Planned cryoneurolysis procedure as part of standard clinical care.\n* Ability to provide written informed consent.\n* Ability and willingness to complete baseline and follow-up questionnaires.\n\nExclusion Criteria:\n\n* Cryoneurolysis performed as part of a separate investigational trial in which data sharing is not permitted.\n* Active infection or other clinical contraindication to the procedure as determined by the treating clinician.\n* Life expectancy of less than 12 months in the judgment of the treating clinician.\n* Any condition that, in the investigator's opinion, would interfere with study participation or completion of follow-up, such as severe psychiatric instability or active substance use that precludes reliable follow-up","ALL","18 Years",{"count":18,"type":19},80,"ESTIMATED","OBSERVATIONAL","To prospectively describe patient-centered and health utilization outcomes through 12 months after cryoneurolysis performed as routine clinical care for chronic pain at Yale.",[23,24,25,26,27,28,29,30,31,32,33,34,35,36],"Chronic Pain","PERIPHERAL NEUROPATHY","Occipital Neuralgia","Chronic Hip Pain","Hip Osteoarthritis","Knee Osteoarthritis","Spasticity","Chronic Low Back Pain","Lumbar Spondylosis","Cervical Spondylosis","Shoulder Arthritis","Causalgia","Chronic Pain Syndrome","Chronic Neck Pain","NOT_YET_RECRUITING","2026-06-05",{"date":40,"type":41},"2026-06-10","ACTUAL",{"date":43,"type":19},"2026-06",{"date":45,"type":19},"2028-07",{"name":47,"class":48},"Yale University","OTHER",{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100588130","phase-3-05-bupivacaine-lower-cervical-intramuscular-injection-vs-iv-medications-for-headache-treatment-100588130","NCT06937385","0.5% Bupivacaine Lower Cervical Intramuscular Injection vs IV Medications for Headache Treatment","Randomized, Prospective, Open-label, Controlled Trial of 0.5% Bupivacaine Lower Cervical Intramuscular Injection vs IV Medications in Treatment of Non-Traumatic Headache in the Emergency Department","Inclusion Criteria:\n\n* Patient has to be able to provide own consent\n* English-speaking only\n* Non traumatic headache with VAS pain score of 5 or above out of 10\n\nExclusion Criteria:\n\n* traumatic headache\n* Confused patients\n* allergy to bupivacaine\n* infection over injection site\n* recent neck surgery\n* hemodynamically unstable\n* bleeding disorder\n* anticoagulation use\n* pregnant, lactating women\n* prisoners",{"count":57,"type":19},100,"INTERVENTIONAL",[60],"PHASE3","Headache is a frequent chief complaint among patients presenting to the Emergency Department (ED), accounting for 2.1 million visits annually in the United States. Often, individuals resort to ED care only after over-the-counter or home remedies have failed, leading to the predominant use of intravenous (IV) medications in the ED, including NSAIDs, triptans, neuroleptics, antiepileptics, and dopaminergic antagonists. Unfortunately, these pharmacologic treatments frequently induce side effects such as cognitive impairment, extrapyramidal reactions, and the potential for medication dependency. In the ED, patients frequently require concurrent administration of multiple systemic medications to achieve satisfactory pain relief, thereby elevating the risk associated with medication use. Despite these medication regimens, a significant portion of patients continue to experience inadequate pain relief. Consequently, the search for an optimal headache therapy-characterized by rapid and effective pain relief, long lasting results, minimal side effects, and allows for rapid ED patient turnover-continues to be a popular area of research in emergency medicine. The investigators plan to evaluate the use of 0.5% bupivacaine cervical IM injection at the c6-7 location for the treatment of non traumatic headaches using a non-inferiority design, randomized, prospective, open-label, controlled trial comparing it to physicians choice of intravenous medications in treatment of headache in the Emergency Department at North Florida Hospital.",[63,64,65,25],"Headache","Migraine","Tension Headache",[67,68,69,70],"headache","bupivicaine","cervical injection","paraspinous injection","2025-04-21",{"date":73,"type":41},"2025-04-24",{"date":75,"type":19},"2025-05-01",{"date":77,"type":19},"2026-05-01",{"name":79,"class":48},"HCA Florida North Florida Hospital",1]